<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30255">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094417</url>
  </required_header>
  <id_info>
    <org_study_id>531-KR001</org_study_id>
    <nct_id>NCT02094417</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Korea Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Korea Co., Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be conducted to evaluate the efficacy and safety of AMG531 and to
      determine the recommended initial dose of AMG531 on the basis of its efficacy and safety
      when it is administered subcutaneously (SC) to the Aplastic Anemia (AA) patients with
      immunosuppressive-therapy refractory thrombocytopenia and also to assess the
      pharmacokinetics of this product. Its efficacy and safety during the extension period will
      also be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects achieving a platelet response</measure>
    <time_frame>At week 9</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving a platelet response</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who become platelet transfusion independent</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving erythroid response</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving neutrophil response</measure>
    <time_frame>52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) bleeding scale</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of Pharmacokinetics</measure>
    <time_frame>Weeks 1, 4, and 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetic parameters, including time to maximum concentration (Tmax),  maximum concentration (Cmax) and area under the curve (AUC)0-t, will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of adverse events</measure>
    <time_frame>52 weeks + 4 weeks follow-up</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of neutralizing antibody</measure>
    <time_frame>52 weeks + 4 weeks follow-up</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>AMG531 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG531 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG531 (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG531 (Dose 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG531</intervention_name>
    <description>Subcutaneous, weekly injection</description>
    <arm_group_label>AMG531 (Dose 3)</arm_group_label>
    <arm_group_label>AMG531 (Dose 1)</arm_group_label>
    <arm_group_label>AMG531 (Dose 2)</arm_group_label>
    <arm_group_label>AMG531 (Dose 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who is diagnosed as AA and refractory to immunosuppressive therapy

          -  Platelet ≤ 30,000/μL

        Exclusion Criteria:

          -  Concurrent active infection not adequately responding to appropriate therapy

          -  HIV positivity

          -  Bone marrow reticulin grade of &gt; 1

          -  Clinically significant cardiac disease

          -  Arterial or venous thrombosis within the last 1 year before enrollment

          -  Other cause of thrombocytopenia

          -  AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)

          -  Uncontrolled diabetes

          -  Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG +
             cyclosporine within 6 months before starting study treatment and/or cyclosporine or
             anabolic hormone within 6 weeks before starting the study treatment

          -  History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other
             thrombopoietin (TPO)-receptor agonist

          -  Who plans to conduct hematopoietic stem cell transplantation within 1 year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Hakko Kirin Korea Co., Ltd</last_name>
    <email>clinical.info@kyowa-kirin.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Hakko Kirin Korea Co., Ltd</last_name>
      <email>clinial.info@kyowa-kirin.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyowa Hakko Kirin Korea Co., Ltd</last_name>
      <email>clinical.info@kyowa-kirin.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anemia, Aplastic</keyword>
  <keyword>Thrombopoietin</keyword>
  <keyword>Thrombocytopenia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
